Menu
Currency
GWAS Study

Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.

Lewis JP, Ryan K, O'Connell JR et al.

23392654 PubMed ID
GWAS Study Type
1792 Participants
68 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

LJ
Lewis JP
RK
Ryan K
OJ
O'Connell JR
HR
Horenstein RB
DC
Damcott CM
GQ
Gibson Q
PT
Pollin TI
MB
Mitchell BD
BA
Beitelshees AL
PR
Pakzy R
TK
Tanner K
PA
Parsa A
TU
Tantry US
BK
Bliden KP
PW
Post WS
FN
Faraday N
HW
Herzog W
GY
Gong Y
PC
Pepine CJ
JJ
Johnson JA
GP
Gurbel PA
SA
Shuldiner AR
Chapter II

Abstract

Summary of the research findings

BACKGROUND- Aspirin or dual antiplatelet therapy with aspirin and clopidogrel is a standard therapy for patients who are at increased risk for cardiovascular events. However, the genetic determinants of variable response to aspirin (alone and in combination with clopidogrel) are not known. METHODS AND RESULTS- We measured ex vivo platelet aggregation before and after dual antiplatelet therapy in individuals (n=565) from the Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study and conducted a genome-wide association study of drug response. Significant findings were extended by examining genotype and cardiovascular outcomes in 2 independent aspirin-treated cohorts: 227 percutaneous coronary intervention patients and 1000 patients of the International Verapamil SR/Trandolapril Study (INVEST) Genetic Substudy (INVEST-GENES). Results from the genome-wide association study revealed a strong association between single-nucleotide polymorphisms on chromosome 1q23 and post-dual antiplatelet therapyplatelet aggregation. Further genotyping revealed rs12041331 in the platelet endothelial aggregation receptor-1 (PEAR1) gene to be most strongly associated with dual antiplatelet therapy response (P=7.66×10(-9)). In white and black patients undergoing percutaneous coronary intervention, A-allele carriers of rs12041331 were more likely to experience a cardiovascular event or death compared with GG homozygotes (hazard ratio, 2.62; 95% confidence interval, 0.96-7.10; P=0.059; and hazard ratio, 3.97; 95% confidence interval, 1.10-14.31; P=0.035, respectively). In aspirin-treated INVEST-GENES patients, rs12041331 A-allele carriers had significantly increased risk of myocardial infarction compared with GG homozygotes (odds ratio, 2.03; 95% confidence interval, 1.01-4.09; P=0.048). CONCLUSION- Common genetic variation in PEAR1 may be a determinant of platelet response and cardiovascular events in patients on aspirin alone or in combination with clopidogrel. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00799396 and NCT00370045.

565 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

1792
Total Participants
GWAS
Study Type
Yes
Replicated
710 European ancestry individuals, 237 African American individuals, 276 Hispanic individuals, 4 individuals
Replication Participants
Hispanic or Latin American, European, African American or Afro-Caribbean, Other
Ancestry
Puerto Rico, U.S.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.